Krystal Biotech Inc
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Pittsburgh, Commonwealth of Pennsylvania, on February 26, 2024.
| KRYSTAL BIOTECH, INC. | |
| By: | /s/ Krish S. Krishnan |
| Krish S. Krishnan | |
| President and Chief Executive Officer | |
| By: | /s/ Kathryn A. Romano |
| Kathryn A. Romano | |
| Chief Accounting Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Krish S. Krishnan and/or Kathryn A. Romano as his or her true and lawful attorney-in-fact and agent, with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Krish S. Krishnan | President and Chief Executive Officer and Director (Principal Executive Officer) | February 26, 2024 |
| Krish S. Krishnan | ||
| /s/ Kathryn A. Romano | Chief Accounting Officer (Principal Financial Officer) | February 26, 2024 |
| Kathryn A. Romano | ||
| /s/ Suma M. Krishnan | President, R&D and Director | February 26, 2024 |
| Suma M. Krishnan | ||
| /s/ Daniel S. Janney | Director | February 26, 2024 |
| Daniel S. Janney | ||
| /s/ Dino A. Rossi | Director | February 26, 2024 |
| Dino A. Rossi | ||
| /s/ Kirti Ganorkar | Director | February 26, 2024 |
| Kirti Ganorkar | ||
| /s/ Julian Gangolli | Director | February 26, 2024 |
| Julian Gangolli | ||
| /s/ Chris Mason | Director | February 26, 2024 |
| Chris Mason | ||
| /s/ E. Rand Sutherland | Director | February 26, 2024 |
| E. Rand Sutherland | ||
| /s/ Catherine Mazzacco | Director | February 26, 2024 |
| Catherine Mazzacco | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.